Fecal Microbiota Transplantation: An Interest in IBD?
Fecal microbiota transplantation (FMT) is a targeted microbiome-based therapy that has garnered a great deal of attention from the scientific, clinical, and lay communities. An increasing number of studies have demonstrated that FMT is a highly effective therapy for recurrent/refractory Clostridium...
Gespeichert in:
| Veröffentlicht in: | Nestle Nutrition Institute workshop series 2014-01, Vol.79, p.101-114 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | |
| container_start_page | 101 |
| container_title | Nestle Nutrition Institute workshop series |
| container_volume | 79 |
| creator | Kahn, Stacy A. Goeppinger, Sarah R. Rubin, David T. |
| description | Fecal microbiota transplantation (FMT) is a targeted microbiome-based therapy that has garnered a great deal of attention from the scientific, clinical, and lay communities. An increasing number of studies have demonstrated that FMT is a highly effective therapy for recurrent/refractory Clostridium difficile infection and appears safe in the short term. Uncontrolled reports suggest the possibility of benefit in a select group of IBD patients, but there is quite limited information so far. FMT for IBD raises significant issues and concerns that warrant further systematic investigation. In this review, we discuss the background and rationale for this innovative therapy, the current knowledge for FMT in IBD, the logistical issues, and the important issues regarding ethics, social acceptability, and regulation. |
| doi_str_mv | 10.1159/000360715 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_karge</sourceid><recordid>TN_cdi_karger_ebooksseries_360715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25227298</sourcerecordid><originalsourceid>FETCH-LOGICAL-k237t-81e267c78a17c6dcff586a54fe03fffdc38e0842eca70a9e732dee75ff5a612f3</originalsourceid><addsrcrecordid>eNpNkMlOwzAURc0kWpUs-AEUPiDgIR7CBpVCoVIRm7KOHOcZmaRJZLsL_p5IAcTqXekeXR09hC4JviGEF7cYYyawJPwIJYVUjBGFqZCYHqM5ESLPKOH85H8nCnH61-VyhpIQPscZQhUvmDxHM8oplbRQc8TXYHSbvjrj-8r1Uac7r7swtLqLOrq-u0uXXbrpIngIMXVjfni8v0BnVrcBkp-7QO_rp93qJdu-PW9Wy23WUCZjpgiMpkYqTaQRtbGWK6F5bgEza21tmAKscjoqSKwLkIzWAJKPnBaEWrZAV9PucKj2UJeDd3vtv8pf_xG4noBG-w_wJVR934QA3kEop7exb6qxVvU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Fecal Microbiota Transplantation: An Interest in IBD?</title><source>eBooks on EBSCOhost</source><source>Karger eBooks Collection</source><source>MEDLINE</source><creator>Kahn, Stacy A. ; Goeppinger, Sarah R. ; Rubin, David T.</creator><contributor>Ruemmele FM ; Wu GD ; Lewis JD</contributor><creatorcontrib>Kahn, Stacy A. ; Goeppinger, Sarah R. ; Rubin, David T. ; Ruemmele FM ; Wu GD ; Lewis JD</creatorcontrib><description>Fecal microbiota transplantation (FMT) is a targeted microbiome-based therapy that has garnered a great deal of attention from the scientific, clinical, and lay communities. An increasing number of studies have demonstrated that FMT is a highly effective therapy for recurrent/refractory Clostridium difficile infection and appears safe in the short term. Uncontrolled reports suggest the possibility of benefit in a select group of IBD patients, but there is quite limited information so far. FMT for IBD raises significant issues and concerns that warrant further systematic investigation. In this review, we discuss the background and rationale for this innovative therapy, the current knowledge for FMT in IBD, the logistical issues, and the important issues regarding ethics, social acceptability, and regulation.</description><identifier>ISSN: 1664-2147</identifier><identifier>ISBN: 9783318026696</identifier><identifier>ISBN: 3318026697</identifier><identifier>EISSN: 1664-2155</identifier><identifier>EISBN: 9783318026702</identifier><identifier>EISBN: 3318026700</identifier><identifier>DOI: 10.1159/000360715</identifier><identifier>PMID: 25227298</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Chapter ; Clostridium Infections - therapy ; Feces - microbiology ; Humans ; Inflammatory Bowel Diseases - microbiology ; Inflammatory Bowel Diseases - therapy ; Microbiota</subject><ispartof>Nestle Nutrition Institute workshop series, 2014-01, Vol.79, p.101-114</ispartof><rights>2014 Nestec Ltd., Vevey/S. Karger AG, Basel</rights><rights>2014 Nestec Ltd., Vevey/S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>779,780,784,793,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25227298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ruemmele FM</contributor><contributor>Wu GD</contributor><contributor>Lewis JD</contributor><creatorcontrib>Kahn, Stacy A.</creatorcontrib><creatorcontrib>Goeppinger, Sarah R.</creatorcontrib><creatorcontrib>Rubin, David T.</creatorcontrib><title>Fecal Microbiota Transplantation: An Interest in IBD?</title><title>Nestle Nutrition Institute workshop series</title><addtitle>Nestle Nutr Inst Workshop Ser</addtitle><description>Fecal microbiota transplantation (FMT) is a targeted microbiome-based therapy that has garnered a great deal of attention from the scientific, clinical, and lay communities. An increasing number of studies have demonstrated that FMT is a highly effective therapy for recurrent/refractory Clostridium difficile infection and appears safe in the short term. Uncontrolled reports suggest the possibility of benefit in a select group of IBD patients, but there is quite limited information so far. FMT for IBD raises significant issues and concerns that warrant further systematic investigation. In this review, we discuss the background and rationale for this innovative therapy, the current knowledge for FMT in IBD, the logistical issues, and the important issues regarding ethics, social acceptability, and regulation.</description><subject>Chapter</subject><subject>Clostridium Infections - therapy</subject><subject>Feces - microbiology</subject><subject>Humans</subject><subject>Inflammatory Bowel Diseases - microbiology</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Microbiota</subject><issn>1664-2147</issn><issn>1664-2155</issn><isbn>9783318026696</isbn><isbn>3318026697</isbn><isbn>9783318026702</isbn><isbn>3318026700</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMlOwzAURc0kWpUs-AEUPiDgIR7CBpVCoVIRm7KOHOcZmaRJZLsL_p5IAcTqXekeXR09hC4JviGEF7cYYyawJPwIJYVUjBGFqZCYHqM5ESLPKOH85H8nCnH61-VyhpIQPscZQhUvmDxHM8oplbRQc8TXYHSbvjrj-8r1Uac7r7swtLqLOrq-u0uXXbrpIngIMXVjfni8v0BnVrcBkp-7QO_rp93qJdu-PW9Wy23WUCZjpgiMpkYqTaQRtbGWK6F5bgEza21tmAKscjoqSKwLkIzWAJKPnBaEWrZAV9PucKj2UJeDd3vtv8pf_xG4noBG-w_wJVR934QA3kEop7exb6qxVvU</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Kahn, Stacy A.</creator><creator>Goeppinger, Sarah R.</creator><creator>Rubin, David T.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20140101</creationdate><title>Fecal Microbiota Transplantation: An Interest in IBD?</title><author>Kahn, Stacy A. ; Goeppinger, Sarah R. ; Rubin, David T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-k237t-81e267c78a17c6dcff586a54fe03fffdc38e0842eca70a9e732dee75ff5a612f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Chapter</topic><topic>Clostridium Infections - therapy</topic><topic>Feces - microbiology</topic><topic>Humans</topic><topic>Inflammatory Bowel Diseases - microbiology</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Microbiota</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kahn, Stacy A.</creatorcontrib><creatorcontrib>Goeppinger, Sarah R.</creatorcontrib><creatorcontrib>Rubin, David T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Nestle Nutrition Institute workshop series</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kahn, Stacy A.</au><au>Goeppinger, Sarah R.</au><au>Rubin, David T.</au><au>Ruemmele FM</au><au>Wu GD</au><au>Lewis JD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fecal Microbiota Transplantation: An Interest in IBD?</atitle><jtitle>Nestle Nutrition Institute workshop series</jtitle><addtitle>Nestle Nutr Inst Workshop Ser</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>79</volume><spage>101</spage><epage>114</epage><pages>101-114</pages><issn>1664-2147</issn><eissn>1664-2155</eissn><isbn>9783318026696</isbn><isbn>3318026697</isbn><eisbn>9783318026702</eisbn><eisbn>3318026700</eisbn><abstract>Fecal microbiota transplantation (FMT) is a targeted microbiome-based therapy that has garnered a great deal of attention from the scientific, clinical, and lay communities. An increasing number of studies have demonstrated that FMT is a highly effective therapy for recurrent/refractory Clostridium difficile infection and appears safe in the short term. Uncontrolled reports suggest the possibility of benefit in a select group of IBD patients, but there is quite limited information so far. FMT for IBD raises significant issues and concerns that warrant further systematic investigation. In this review, we discuss the background and rationale for this innovative therapy, the current knowledge for FMT in IBD, the logistical issues, and the important issues regarding ethics, social acceptability, and regulation.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>25227298</pmid><doi>10.1159/000360715</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1664-2147 |
| ispartof | Nestle Nutrition Institute workshop series, 2014-01, Vol.79, p.101-114 |
| issn | 1664-2147 1664-2155 |
| language | eng |
| recordid | cdi_karger_ebooksseries_360715 |
| source | eBooks on EBSCOhost; Karger eBooks Collection; MEDLINE |
| subjects | Chapter Clostridium Infections - therapy Feces - microbiology Humans Inflammatory Bowel Diseases - microbiology Inflammatory Bowel Diseases - therapy Microbiota |
| title | Fecal Microbiota Transplantation: An Interest in IBD? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A35%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fecal%20Microbiota%20Transplantation:%20An%20Interest%20in%20IBD?&rft.jtitle=Nestle%20Nutrition%20Institute%20workshop%20series&rft.au=Kahn,%20Stacy%20A.&rft.date=2014-01-01&rft.volume=79&rft.spage=101&rft.epage=114&rft.pages=101-114&rft.issn=1664-2147&rft.eissn=1664-2155&rft.isbn=9783318026696&rft.isbn_list=3318026697&rft_id=info:doi/10.1159/000360715&rft_dat=%3Cpubmed_karge%3E25227298%3C/pubmed_karge%3E%3Curl%3E%3C/url%3E&rft.eisbn=9783318026702&rft.eisbn_list=3318026700&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25227298&rfr_iscdi=true |